Skip to main
INFU
INFU logo

InfuSystem Hlds (INFU) Stock Forecast & Price Target

InfuSystem Hlds (INFU) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

InfuSystems Holdings, Inc. has reported record quarterly revenue growth in its core oncology business, enhanced by a new contract with a large hospital system expected to increase patient volumes in the upcoming quarter. The company's gross profit margin improved significantly by 370 basis points to 55.2%, attributed to an optimized revenue mix and normalized costs, which reflects operational efficiency. Additionally, year-to-date net operating cash flow reached $17.3 million, showing a 38% increase that underscores improved earnings and effective working capital management, setting a positive trajectory for future growth.

Bears say

InfuSystems Holdings Inc. is facing a challenging financial landscape characterized by declining gross margins, particularly within its Device Solutions division, alongside rising operational costs. Economic uncertainties have exacerbated this situation, leading to customer destocking that has reduced both demand and sales volumes, thereby exerting further pressure on margins. Revenue estimates for FY26 have been adjusted downward by $9.5 million, remaining flat compared to FY25, highlighting the company's struggles amid competitive headwinds and decreasing sales productivity.

InfuSystem Hlds (INFU) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of InfuSystem Hlds and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About InfuSystem Hlds (INFU) Forecast

Analysts have given InfuSystem Hlds (INFU) a Strong Buy based on their latest research and market trends.

According to 2 analysts, InfuSystem Hlds (INFU) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

InfuSystem Hlds (INFU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.